Signpath Pharma is a clinical-stage company with a unique drug development platform that specializes in creating heart-safe drugs. Their groundbreaking technology, known as the CorreQT platform, is designed to mitigate the cardiac side effects of various medications, including cardiac arrhythmia and cardiac damage caused by chemotherapy. One of their leading products is LipoCurc™, the first clinical application of their CorreQT platform.

LipoCurc™ is a proprietary liposomal formulation of curcumin that is administered intravenously. It provides active and sustained levels of curcumin that are over 1000 times greater than traditional oral dosing, without the usual cardiotoxicity associated with intravenous administration. In clinical trials, LipoCurc™ has demonstrated promising results, showing no cardiac toxicity and signs of efficacy in end-stage cancer patients.

Additionally, Signpath Pharma is developing SPP4040, a lipid-based drug administered orally, which eliminates dangerous cardiac arrhythmia and cardiac muscle damage commonly seen with other medications. This innovative CorreQT platform allows Signpath to create next-generation, patented drugs across multiple classes, including anti-cancer agents, antibiotics, antipsychotics, and antihistamines. Headquartered in Sandy, Utah, Signpath Pharma has partnerships and collaborations worldwide.

Their mission is to address significant unmet medical needs by bringing innovative treatments through clinical trials and into the marketplace